Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Equecabtagene Autoleucel vs DPd/PVd in Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma
jRCT2033260362Phase 3Not yet recruiting
- Sponsor
- Reindeer Biotech
- Start
- Oct 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 2
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing Equecabtagene autoleucel arm with Standard-of-care DPd or PVd arm (2 arms). Primary endpoint: Progression-free survival (PFS). Planned start Oct 2026; status: not yet recruiting.
02
Drugs
equecabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2033260362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033260362.